HP
VKTX icon

Hikari Power’s Viking Therapeutics VKTX Stock Holding History

Hikari Power’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-50,000
Closed -$415K – 122
2019
Q2 		$415K Hold
50,000
– – 0.04% 80
2019
Q1 		$497K Buy
50,000
+10,000
+25% +$83.7K 0.05% 72
2018
Q4 		$306K Buy
+40,000
New +$478K 0.03% 84

Other funds holding VKTX

ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Hikari Power's VKTX Position: Q3 2019 in Review

Hikari Power sold out of Viking Therapeutics (VKTX) in Q3 2019, closing a stake of 50,000 shares — an estimated $415K sold.

Hikari Power first reported a position in VKTX in Q4 2018 and held it in 3 quarters. The position peaked at $497K in Q1 2019. 144 funds tracked by Wall St. Rank hold VKTX as of Q3 2019.

  • Hikari Power reported no remaining Viking Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Hikari Power sold 50,000 Viking Therapeutics shares in Q3 2019, an estimated $415K.
  • Hikari Power first reported a position in Viking Therapeutics in Q4 2018 and held it in 3 quarters.
  • Hikari Power's Viking Therapeutics position peaked at $497K in Q1 2019.
  • 144 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2019.

Based on Hikari Power's 13F filing for Q3 2019, filed 31 Oct 2019.